RecruitingEarly Phase 1NCT05996432

Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

Non-invasive, Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy


Sponsor

Vanderbilt-Ingram Cancer Center

Enrollment

48 participants

Start Date

May 17, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using a special imaging technique to measure oxygen levels inside tumors (tumor hypoxia — areas of the tumor that lack oxygen), and then using that information to customize radiation therapy for head and neck cancer or brain metastases. Tumors with low oxygen are harder to treat, so targeting those areas with higher doses may improve outcomes. **You may be eligible if...** - You have head and neck squamous cell carcinoma or brain metastases confirmed by a pathology test or clinical diagnosis - You have at least one measurable tumor - You are in good overall health (ECOG 0–1 or Karnofsky score ≥70%) - Your life expectancy is at least 6 months **You may NOT be eligible if...** - You are in poor health - Your tumor cannot be measured on a scan - You are pregnant or may become pregnant (due to radiation risks) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREMagnetic Resonance Imaging (MRI)

Participants will undergo Magnetic Resonance Imaging

PROCEDUREPositron Emission Tomography (PET)

Participants will undergo Positron Emission Tomography

DRUG18F-fluoromisonidazole

Given by IV


Locations(1)

Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05996432


Related Trials